Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2018, Article ID 1632978, 11 pages
https://doi.org/10.1155/2018/1632978
Research Article

High-Grade Osteosarcoma of the Foot: Presentation, Treatment, Prognostic Factors, and Outcome of 23 Cooperative Osteosarcoma Study Group COSS Patients

1Center for Pediatric, Adolescent and Women's Medicine, Olgahospital, Department of Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart, Stuttgart, Germany
2St. Anna Children’s Hospital, Department of Paediatrics, Medical University of Vienna and Children’s Cancer Research Institute (CCRI), Vienna, Austria
3Department of Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Berlin, Germany
4Bone Tumour Reference Centre (BTRC), Institute of Pathology, University Hospital of Basel and University of Basel, Basel, Switzerland
52nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
6Department of Pathology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
7Department of Hematology and Oncology, Klinikum rechts der Isar Technische Universität München, Munich, Germany
8Department of Internal Medicine III, University of Ulm, Ulm, Germany
9Center for Pediatric, Adolescent and Women’s Medicine, Olgahospital, Department of Pediatric Radiology, Klinikum Stuttgart, Stuttgart, Germany
10Department of Orthopaedics, Medical University of Vienna, Vienna, Austria
11Center for Pediatric, Adolescent and Women’s Medicine, Olgahospital, Department of Pediatrics, Division of Pediatric Orthopedics, Klinikum Stuttgart, Stuttgart, Germany
12Department of Pediatric Hematology and Oncology, University Children’s Hospital Muenster, Muenster, Germany

Correspondence should be addressed to Anne J. Schuster; ed.tragttuts-mukinilk@retsuhcs.enna

Received 21 November 2017; Revised 15 February 2018; Accepted 18 March 2018; Published 2 May 2018

Academic Editor: Valerae O. Lewis

Copyright © 2018 Anne J. Schuster et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. K. Anninga, P. Picci, M. Fiocco et al., “Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup,” Virchows Archiv, vol. 462, no. 1, pp. 109–120, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Biscaglia, A. Gasbarrini, T. Böhling, P. Bacchini, F. Bertoni, and P. Picci, “Osteosarcoma of the bones of the foot–an easily misdiagnosed malignant tumor,” Mayo Clinic proceedings, vol. 73, no. 9, pp. 842–847, 1998. View at Publisher · View at Google Scholar
  3. H. M. Ozdemir, Y. Yildiz, C. Yilmaz, and Y. Saglik, “Tumors of the foot and ankle: analysis of 196 cases,” Journal of Foot and Ankle Surgery, vol. 36, no. 6, pp. 403–408, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Brotzmann, F. Hefti, D. Baumhoer, and A. H. Krieg, “Do malignant bone tumors of the foot have a different biological behavior than sarcomas at other skeletal sites?” Sarcoma, vol. 2013, Article ID 767960, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. P. F. Choong, A. A. Qureshi, F. H. Sim, and K. K. Unni, “Osteosarcoma of the foot: a review of 52 patients at the Mayo Clinic,” Acta Orthopaedica Scandinavica, vol. 70, no. 4, pp. 361–364, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. L. B. Chou, Y. Y. Ho, and M. M. Malawer, “Tumors of the foot and ankle: experience with 153 cases,” Foot & Ankle International, vol. 30, no. 9, pp. 836–841, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Casadei, A. Ferraro, A. Ferruzzi, R. Biagini, and P. Ruggieri, “Bone tumors of the foot: epidemiology and diagnosis,” La Chirurgia degli Organi di Movimento, vol. 76, no. 1, pp. 47–62, 1991. View at Google Scholar
  8. R. Eyre, R. G. Feltbower, P. W. James et al., “The epidemiology of bone cancer in 0-39 year olds in northern England, 1981–2002,” BMC Cancer, vol. 10, no. 1, p. 357, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Winkler, G. Beron, G. Schellong et al., “Cooperative osteosarcoma study COSS-77: results after 4 years,” Klinische Padiatrie, vol. 194, no. 4, pp. 251–256, 1982. View at Publisher · View at Google Scholar
  10. K. Winkler, G. Beron, R. Kotz et al., “Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study,” Journal of Clinical Oncology, vol. 2, no. 6, pp. 617–624, 1984. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Winkler, G. Beron, G. Delling et al., “Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response,” Journal of Clinical Oncology, vol. 6, no. 2, pp. 329–337, 1988. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Fuchs, S. S. Bielack, D. Epler et al., “Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs,” Annals of Oncology, vol. 9, no. 8, pp. 893–899, 1998. View at Google Scholar
  13. B. S. S. Bielack, B. Kempf-bielack, G. U. Exner et al., “Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 776–790, 2002. View at Publisher · View at Google Scholar
  14. S. Bielack, H. Jürgens, G. Jundt et al., “Osteosarcoma: the COSS experience,” Cancer Treatment and Research, vol. 152, no. 7, pp. 289–308, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. S. Whelan, S. S. Bielack, N. Marina et al., “EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment,” Annals of Oncology, vol. 26, no. 2, pp. 407–414, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Bielack, S. Flege, and B. Kempf-Bielack, “Behandlungskonzept des osteosarkoms,” Der Onkologe, vol. 6, no. 8, pp. 747–758, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Carrle and S. S. Bielack, “Current strategies of chemotherapy in osteosarcoma,” International Orthopaedics, vol. 30, no. 6, pp. 445–451, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. W. F. Enneking, S. S. Spanier, and M. A. Goodman, “Current concepts review: the surgical staging of musculoskeletal sarcoma,” Journal of Bone and Joint Surgery, vol. 62, no. 6, pp. 1027–1030, 1980. View at Publisher · View at Google Scholar
  19. M. Salzer-Kuntschik, G. Delling, G. Beron, and R. Sigmund, “Morphological grades of regression in osteosarcoma after polychemotherapy? Study COSS 80,” Journal of Cancer Research and Clinical Oncology, vol. 106, no. S1, pp. 21–24, 1983. View at Publisher · View at Google Scholar · View at Scopus
  20. E. L. Kaplan and P. Meier, “Nonparametric estimation from incomplete observations,” Journal of the American Statistical Association, vol. 53, no. 282, pp. 457–481, 1958. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Mantel, “Evaluation of survival data and two new rank order statistics arising in its consideration,” Cancer Chemotherapy Reports, vol. 50, no. 3, pp. 163–170, 1966. View at Google Scholar
  22. D. R. Cox, “Regression models and life-tables,” Journal of the Royal Statistical Society: Series B (Methodological), vol. 34, no. 2, pp. 187–220, 1972. View at Google Scholar
  23. F. Wilcoxon, “Individual comparisons of grouped data by ranking methods,” Journal of Economic Entomology, vol. 39, no. 6, pp. 269-270, 1946. View at Publisher · View at Google Scholar
  24. G. Gatta, R. Capocaccia, C. Stiller, P. Kaatsch, F. Berrino, and M. Terenziani, “Childhood cancer survival trends in Europe: a EUROCARE working group study,” Journal of Clinical Oncology, vol. 23, no. 16, pp. 3742–3751, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. C. A. Stiller, S. S. Bielack, G. Jundt, and E. Steliarova-Foucher, “Bone tumours in European children and adolescents, 1978–1997: report from the Automated Childhood Cancer Information System project,” European Journal of Cancer, vol. 42, no. 13, pp. 2124–2135, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Mirabello, R. J. Troisi, and S. A. Savage, “Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program,” Cancer, vol. 115, no. 7, pp. 1531–1543, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Gatta, L. Botta, S. Rossi et al., “Childhood cancer survival in Europe 1999-2007: Results of EUROCARE-5-a population-based study,” The Lancet Oncology, vol. 15, no. 1, pp. 35–47, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Bacci, A. Longhi, M. Versari, M. Mercuri, A. Briccoli, and P. Picci, “Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution,” Cancer, vol. 106, no. 5, pp. 1154–1161, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Kager, A. Zoubek, U. Kastner et al., “Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group,” Journal of Clinical Oncology, vol. 24, no. 10, pp. 1535–1541, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Kager, A. Zoubek, U. Pötschger et al., “Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 2011–2018, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. H.-Y. Ren, L.-L. Sun, H.-Y. Li, and Z.-M. Ye, “Prognostic significance of serum alkaline phosphatase level in osteosarcoma: a meta-analysis of published data,” BioMed Research International, vol. 2015, Article ID 160835, 11 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Bacci, A. Longhi, S. Ferrari et al., “Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years,” Tumori, vol. 90, no. 5, pp. 478–484, 2004. View at Google Scholar
  33. J. S. Whelan, R. C. Jinks, A. McTiernan et al., “Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European osteosarcoma intergroup randomised controlled trials,” Annals of Oncology, vol. 23, no. 6, pp. 1607–1616, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Kempf-Bielack, S. S. Bielack, H. Jürgens et al., “Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS),” Journal of Clinical Oncology, vol. 23, no. 3, pp. 559–568, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Picci, S. Ferrari, G. Bacci, and F. Gherlinzoni, “Treatment recommendations for osteosarcoma and adult soft tissue sarcomas,” Drugs, vol. 47, no. 1, pp. 82–92, 1994. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Weeden, R. J. Grimer, S. R. Cannon et al., “The effect of local recurrence on survival in resected osteosarcoma,” European Journal of Cancer, vol. 37, no. 1, pp. 39–46, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Versluys, A. Desomer, G. Lenaerts et al., “From conventional prosthetic feet to bionic feet: a review study,” in Proceedings of the 2nd IEEE RAS & EMBS International Conference on Biomedical Robotics and Biomechatronics, pp. 49–54, Scottsdale, AZ, USA, October 2008.
  38. M. T. Harting, K. P. Lally, R. J. Andrassy et al., “Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients,” Journal of Cancer Research and Clinical Oncology, vol. 136, no. 4, pp. 561–570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Bacci, M. Rocca, M. Salone et al., “High-grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions,” Journal of Surgical Oncology, vol. 98, no. 6, pp. 415–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. M. San-Julian, P. Diaz-de-Rada, E. Noain, and L. Sierrasesumaga, “Bone metastases from osteosarcoma,” International Orthopaedics, vol. 27, no. 2, pp. 117–120, 2003. View at Google Scholar
  41. P. Bieling, N. Rehan, P. Winkler et al., “Tumor size and prognosis in aggressively treated osteosarcoma,” Journal of Clinical Oncology, vol. 14, no. 3, pp. 848–858, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. S. K. Min, S. Y. Lee, H. C. Wan et al., “Initial tumor size predicts histologic response and survival in localized osteosarcoma patients,” Journal of Surgical Oncology, vol. 97, no. 5, pp. 456–461, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. E. González-Billalabeitia, R. Hitt, J. Fernández et al., “Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma,” Clinical and Translational Oncology, vol. 11, no. 7, pp. 479–483, 2009. View at Publisher · View at Google Scholar · View at Scopus